Drug-induced antibodies during 2-N-methyl-9-hydroxyellipticinium acetate (NSC-264137) treatment: schedule dependency and relationship to hemolysis.
Drug-dependent antibodies were investigated in patients treated with elliptinium acetate, a cytostatic drug with activity in advanced breast cancer. Retrospective analysis of 83 patients, receiving weekly intravenous elliptinium, showed a high incidence of anti-elliptinium antibodies (20%). Hemolysis occurred among antibody-positive patients, apparently related to the antibody titer. The predictability of anti-elliptinium antibodies for hemolysis and the schedule dependency of antibody development was examined prospectively. Among 42 patients treated weekly for at least three courses, 40% developed antibodies. Of 30 patients receiving elliptinium daily for three days every three weeks, none developed either antibodies or hemolysis. Only antibody positive patients, with titers greater than or equal to 32 were at risk for hemolysis. The possible mechanisms are discussed.
D000470:Alkaloids / Q000276:immunology*; D000743:Anemia, Hemolytic / Q000139:chemically induced* / Q000276:immunology; D000906:Antibodies / Q000032:analysis*; D001943:Breast Neoplasms / Q000188:drug therapy; D004611:Ellipticines / Q000009:adverse effects / Q000276:immunology*; D005260:Female; D006801:Humans; D011446:Prospective Studies; D012189:Retrospective Studies; D012306:Risk
D000470:Alkaloids; D000906:Antibodies; D004611:Ellipticines; C027767:elliptinium